Form 4: Lilly Endowment Sells $22.7M in Eli Lilly Stock
Insider Transaction Report
Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 26,795 shares of common stock for approximately $22.7 million, executed under a 10b5-1 plan.
Summary
- Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), reported a sale of common stock.
- 26,795 shares were disposed of on October 7, 2025.
- The shares were sold at a weighted average price of $848.009 per share, with prices ranging from $848.00 to $848.32.
- The total value of the transaction is approximately $22,720,900.55.
- Following this transaction, Lilly Endowment Inc. beneficially owns 94,649,000 shares of Eli Lilly & Co. common stock.
- The transaction was executed pursuant to a Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The sale by Lilly Endowment Inc. is a routine transaction executed under a pre-arranged 10b5-1 trading plan, which typically indicates a non-discretionary sale rather than a reaction to new material information. The amount sold represents a very small fraction of their total beneficial ownership.
Positives
- NA
Negatives
- A 10% owner, Lilly Endowment Inc., sold 26,795 shares of common stock.
- While a small percentage of their total holding, insider selling can sometimes be perceived negatively by the market, even if pre-scheduled.
Risks
- NA
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold 26,795 shares of common stock.
Stakeholder Impact
- Shareholders: May interpret the insider sale as a slight negative signal, though mitigated by the 10b5-1 plan and the relatively small transaction size.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 10/07/2025 | Date of transaction for the sale of common stock. |
| 10/08/2025 | Date of signature for the Form 4 filing. |
Recommendation
holdThe Form 4 reports a routine, pre-scheduled insider sale by a 10% owner under a 10b5-1 plan. This type of transaction is generally not indicative of new material information or a change in the company's fundamental outlook. The amount sold is also a very small fraction of the reporting person's total holdings. Therefore, it does not provide a strong signal for either buying or selling, suggesting a 'hold' recommendation based solely on this filing.
Keywords
Eli Lilly & Co, LLY, Lilly Endowment Inc, Form 4, Insider Sale, Beneficial Ownership, Stock Transaction, Pharmaceuticals, Biotech, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.